Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baxdrostat plus dapagliflozin versus placebo plus dapagliflozin in adults with chronic kidney disease and hypertension
NL-OMON60362Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) and hypertension (HTN) comparing Baxdrostat + dapagliflozin with Placebo + dapagliflozin (2 arms). Primary endpoint: Change from baseline in eGFR to post treatment. Started Jul 2024; status: active, not recruiting.
02
Drugs
baxdrostatdapagliflozin
03
Conditions
chronic kidney disease (CKD)hypertension (HTN)
Beyond the preview
Go deeper on NL-OMON60362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60362.